Home > Inhibitors & Agonists > Others > Other Targets

Other Targets

You can also try the following methods, and our professionals will serve you Customized Consultation
Cat. No. Product Name Field of Application Chemical Structure
DC9512 Lazabemide Featured Lazabemide(Ro 19-6327/000) is selective, reversible monoamine oxidase B (MAO-B) inhibitor (IC50 values are 0.03 and > 100 μM for MAO-B and MAO-A respectively).
DC22765 LB-102 Featured LB-102 (LB-1.2, LB 102) is a a selective dopamine D2/3/5-HT7 inhibitor.
DC21221 LB42908 LB42908 is a highly potent, selective, orally active inhibitor of Ras farnesyltransferase (FTase) with IC50 of 0.9 nM against H-Ras and 2.4 nM against K-Ras..
DC21219 LBL1 LBL1 (Lamin A inhibitor LBL1) is a novel pyrroloquinazoline compound with significant anticancer activity, targets nuclear lamins and binds to the coiled-coil domain of lamin A (Kd=5.11 uM).
DC22135 LC-1028 LC-1028 (LC1028) is a novel potent selective, covalent and irreversible inhibitor of p97 (valosin-containing protein), remains essentially irreversible ac tivity against p97 mutant C522A..
DC21222 LCB 03-0110 LCB 03-0110 is a potent, ATP-competitive inhibitor of Discoidin domain receptor (DDR) family and c-Src tyrosine kinase family, as well as Btk and Syk.
DC21223 LCB 03-0110 dihydrochloride LCB 03-0110 is a potent, ATP-competitive inhibitor of Discoidin domain receptor (DDR) family and c-Src tyrosine kinase family, as well as Btk and Syk.
DC23329 LCH 7749944 Featured LCH 7749944 (GNF-PF-2356) is a novel and potent PAK4 with IC50 of 14.93 uM, shows weak activity against other PAK family members.
DC7184 Lcl-161 Featured LCL161 is an oral small molecule antagonist of Apoptosis Proteins (IAPs) that sensitizes a subset of tumors from diverse lineages to treatment with cytotoxic therapies.
DC20006 LCL521 LCL521 is an acid ceramidase (ACDase) inhibitor. LCL521 also inhibits the lysosomal acid sphingomyelinase (ASMase).
DC21225 LCS-1 LCS-1 is a small molecule that inhibits growth of human lung adenocarcinoma cells harboring mutations in EGFR or KRAS with IC50 of 0.1-1.5 uM.
DC21226 LCS-1.28 LCS-1.28 is a small molecule that inhibits growth of human lung adenocarcinoma cells harboring mutations in EGFR or KRAS with IC50 of 0.05-1.6 uM.
DC21227 LCS-1.34 LCS-1.34 is a small molecule that inhibits growth of human lung adenocarcinoma cells harboring mutations in EGFR or KRAS with IC50 of 0.1-1.1 uM.
DC21228 LDD1937 LDD1937 is a novel potent FLT3 inhibitor with IC50 of 3 nM, displays >170-fold selectivity over JAK2/3, c-MET, IRAK-4.
DC20433 LDHA-IN-104 LDHA-IN-104 is a potent and selective lactate dehydrogenase A (LDHA) inhibitor with IC50 of 0.87 uM, less potent for LDHB (IC50=6.9 uM).
DC21230 LDK1229 LDK1229 is a novel potent, selective cannabinoid CB1 receptor inverse agonist with Ki of 220 nM.
DC5167 Ceritinib(LDK378) Featured LDK378 is a highly selective ALK inhibitor with IC50 of 2 nM
DC23787 LDN 91946 LDN 91946 is a selective, uncompetitive ubiquitin C-terminal hydrolase-L1 (UCH-L1) inhibitor with Ki of 2.8 uM, exhibits no activity against other cysteine hydrolase (UCH-L3, TGase 2, papain and caspase-3)..
DC22459 LDN-109657 LDN-109657 is a novel SMN2 modulator that increase SMN protein levels in 3813 fibroblasts by twofold at 370 nM..
DC8231 LDN-192960 2HCl Featured LDN-192960 is a potent and selective inhibitor of haspin (Haploid Germ Cell-Specific Nuclear Protein Kinase). IC50 = 0.010 µm
DC7452 LDN-211904 LDN-211904 is an inhibitor of erythropoietin-producing hepatocellular carcinoma (Eph) receptors.
DC7586 LDN-212854 Featured LDN-212854 is a potent and selective BMP receptor inhibitor with IC50 of 1.3 nM for ALK2, about 2-, 66-, 1641-, and 7135-fold selectivity over ALK1, ALK3, ALK4, and ALK5, respectively.
DC22460 LDN-75654 LDN-75654 is a novel potent SMN2 modulator (EC50=1.8 uM.
DC22461 LDN-76070 LDN-76070 is a novel potent SMN2 modulator (EC50=8.3 uM.
DC7947 Ledipasvir Featured Ledipasvir(GS5885) is an inhibitor of the hepatitis C virus NS5A protein. Ledipasvir is an experimental drug for the treatment of hepatitis C.
DC12387 Lefamulin acetate Featured Lefamulin acetate is a pleuromutilin antibiotic that is being developed by Nabriva Therapeutics for the treatment of acute bacterial skin and skin-structure infections.
DC8172 Lefamulin(BC-3781) Featured Lefamulin is a semi-synthetic compound that inhibits the synthesis of bacterial protein, which is required for bacteria to grow.
DCAPI1333 Leflunomide Leflunomide
DC21231 LEI-105 LEI-105 is a potent, highly selective, and reversible dual DAGL-α/DAGL-β inhibitor with pIC50 pf 7.5/7.4 respectively.
DC22136 LEI 110 Featured LEI110 (LEI-110) is a potent Phospholipase A2 group XVI (PLA2G16) inhibitor with Ki of 20 nM, also has activity on HRASLS2, RARRES3 and iNAT (pIC50=6.8-7.6).

Customized Consultation X

Your information is safe with us. * Required Fields.

Your name
Company
Email
Procuct Name
Cat. No.
Remark
Verification code
Please fill out the characters in the picture
X